Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Petroni

Showing results (31-40 of 131) with videos related to

Pageof 14
Sort By:
Oncology Nursing Forum|March 3, 2025
Decision Aid Interventions for Contralateral Prophylactic Mastectomy in Women of Average Risk: An Integrative ReviewCrystal Chu, Lynn T Dengel, Gina R Petroni, et al.
The Journal of Urology|September 8, 2001
Prostate specific antigen kinetics at tumor recurrence after radical prostatectomy do not suggest a worse disease prognosis in black menE A Bissonette, B R Fulmer, G R Petroni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1995
Etoposide, vinblastine, and doxorubicin: an active regimen for the treatment of Hodgkin's disease in relapse following MOPP. Cancer and Leukemia Group BG P Canellos, G R Petroni, M Barcos, et al.
Contemporary Clinical Trials Communications|January 16, 2020
Efficient dose-finding for drug combination studies involving a shift in study populationsNolan A Wages, Trish A Millard, Patrick M Dillon, et al.
Academic Radiology|July 26, 2005
Evaluating hormone therapy-associated increases in breast density comparison between reported and simultaneous assignment of BI-RADS categories, visual assessment, and quantitative analysisJennifer A Harvey, Viktor E Bovbjerg, Mark E Smolkin, et al.
Clinical Trials (London, England)|March 30, 2024
Applications of the partial-order continual reassessment method in the early development of treatment combinationsNolan A Wages, Patrick M Dillon, Craig A Portell, et al.
Clinical Trials (London, England)|January 11, 2021
Adapting isotonic dose-finding to a dynamic set of drug combinations with application to a phase I leukemia trialNolan A Wages, Daniel R Reed, Michael K Keng, et al.
The Oncologist|June 16, 2025
Patient-reported tolerance of 90 days of preoperative endocrine therapy: results from the preoperative window of endocrine therapy to inform radiation therapy decisions trialTrish Millard, Lena M Turkheimer, Jenna Schlefman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1986
Prognostic factors in advanced ovarian carcinomaJ R Redman, G R Petroni, P E Saigo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2017
Implementation of a Model-Based Design in a Phase Ib Study of Combined Targeted AgentsNolan A Wages, Craig A Portell, Michael E Williams, et al.
Pageof 14

Showing results (31-40 of 131) with videos related to

Sort By:
Pageof 14
Oncology Nursing Forum|March 3, 2025
Decision Aid Interventions for Contralateral Prophylactic Mastectomy in Women of Average Risk: An Integrative ReviewCrystal Chu, Lynn T Dengel, Gina R Petroni, et al.
The Journal of Urology|September 8, 2001
Prostate specific antigen kinetics at tumor recurrence after radical prostatectomy do not suggest a worse disease prognosis in black menE A Bissonette, B R Fulmer, G R Petroni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1995
Etoposide, vinblastine, and doxorubicin: an active regimen for the treatment of Hodgkin's disease in relapse following MOPP. Cancer and Leukemia Group BG P Canellos, G R Petroni, M Barcos, et al.
Contemporary Clinical Trials Communications|January 16, 2020
Efficient dose-finding for drug combination studies involving a shift in study populationsNolan A Wages, Trish A Millard, Patrick M Dillon, et al.
Academic Radiology|July 26, 2005
Evaluating hormone therapy-associated increases in breast density comparison between reported and simultaneous assignment of BI-RADS categories, visual assessment, and quantitative analysisJennifer A Harvey, Viktor E Bovbjerg, Mark E Smolkin, et al.
Clinical Trials (London, England)|March 30, 2024
Applications of the partial-order continual reassessment method in the early development of treatment combinationsNolan A Wages, Patrick M Dillon, Craig A Portell, et al.
Clinical Trials (London, England)|January 11, 2021
Adapting isotonic dose-finding to a dynamic set of drug combinations with application to a phase I leukemia trialNolan A Wages, Daniel R Reed, Michael K Keng, et al.
The Oncologist|June 16, 2025
Patient-reported tolerance of 90 days of preoperative endocrine therapy: results from the preoperative window of endocrine therapy to inform radiation therapy decisions trialTrish Millard, Lena M Turkheimer, Jenna Schlefman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1986
Prognostic factors in advanced ovarian carcinomaJ R Redman, G R Petroni, P E Saigo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2017
Implementation of a Model-Based Design in a Phase Ib Study of Combined Targeted AgentsNolan A Wages, Craig A Portell, Michael E Williams, et al.
Pageof 14